Articles from BioSkryb Genomics

BioSkryb Genomics, a pioneer in single-cell and ultra–low-input multi-omic solutions, and Ultima Genomics, a leader in scalable and cost-effective sequencing, today announced a collaboration designed to accelerate next-generation oncology research. By combining BioSkryb’s best-in-class single-cell amplification and multi-omic platforms with Ultima’s ultra-high-throughput, cost-efficient sequencing technology, this collaboration aims to provide researchers with comprehensive, high-resolution insights into complex cancer genomics, ultimately driving discoveries that can inform improved patient outcomes.

BioSkryb Genomics, a pioneer in single-cell and ultra-low input multiomics is excited to announce the launch of ResolveSEQ MRD, an innovative service offering designed to empower further classification and characterization of the MRD cells for hematologic malignancies. ResolveSEQ MRD integrates seamlessly with established flow cytometry (FC) protocols to provide unparalleled single-cell genome and transcriptome characterization, offering deeper biological insights to drive greater discoveries in precision oncology.

BioSkryb Genomics, a company ushering in the next generation of single-cell technology, today announced a partnership with the Human Cell Atlas (HCA), a global consortium that is mapping every cell type in the human body, creating a 3-dimensional Atlas of human cells to transform our understanding of biology and disease.

BioSkryb Genomics, a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer Research® (AACR) Annual Meeting 2024 on April 5-10, 2024 in San Diego, CA.

BioSkryb Genomics, a company ushering in the next generation of single-cell technology, today announced the commercial launch of its new ResolveDNA Whole Genome and ResolveOME Whole Genome and Transcriptome Single-Cell Core Kits, which are now available to U.S. and international customers.

BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete DNA-informed multiomic view of the cellular ecosystem, today announced that it will introduce innovative new products and present novel research at the AGBT 2024 General Meeting on February 5-8, 2024 in Orlando, Florida. As a Bronze Sponsor, BioSkryb will also host a workshop and networking event at the meeting.

BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, has appointed Ram Laxman, Ph.D., as Chief Commercial Officer. Dr. Laxman will lead sales and support, commercial strategy and operations, and marketing as BioSkryb continues to scale its global presence. He brings strong executive leadership experience and an extensive track record of building and scaling businesses at companies like 10x Genomics, Pacific Biosciences, and Illumina.

BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, today announced that it will share a wide range of new research related to its recent single-cell multiomic data, single-cell whole genome sequencing and comprehensive multiomic profiling at the ASHG 2023 Annual Meeting in Washington, D.C.

BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, today announced it has joined the NIST Genome Editing Consortium to help address the measurements and standards needed to increase confidence of utilizing genome editing technologies in research and commercial products.

BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, today announced a partnership with Research Instruments Pte Ltd, a premier distributor for genomic and life science research products in Southeast Asia, to distribute BioSkryb’s ResolveDNA® and ResolveOME™ single cell amplification tools throughout Singapore and Southeast Asia. Research Instruments (“Everlife-RI") is part of Everlife Asia, a leading Asia-focused market access and distribution group with strong capabilities in life sciences, clinical diagnostics, and analytical instrumentation operating in seven countries across Asia.

BioSkryb Genomics, a company transforming single-cell analysis by enabling the most complete multiomic view of the cellular ecosystem, from discovery to diagnostics, today announced the issuance of a composition of matter patent, US Patent 11,643,682 by the U.S. Patent and Trademark Office related to its novel Primary Template-Directed Amplification (PTA) method and applications for research, diagnostics, and treatment. The patent is exclusively licensed to BioSkryb by St. Jude Children’s Research Hospital.

BioSkryb Genomics, a pioneer in comprehensive single-cell multiomic research solutions, optimized a high-throughput workflow of BioSkryb’s ResolveDNA® Single-Cell Whole Genome Amplification technology on HP’s new D100 Single Cell Dispenser to deliver single-cell genomics at scale.

BioSkryb Genomics, a pioneer in comprehensive single-cell multiomic research solutions, today announced that it will share new, groundbreaking research related to single-cell analysis of breast cancer biopsies and the expansion of its ResolveDNA® product line at the AACR 2023 Annual Meeting in Orlando, Florida.

BioSkryb Genomics, a pioneer in comprehensive single cell multiomic research solutions, today announced the commercial launch of its ResolveOME™ Whole Genome and Transcriptome Amplification system and BaseJumper™ Bioinformatics Platform at the Advances in Genome Biology and Technology (AGBT) 2023 General Meeting.

BioSkryb Genomics, a pioneer in comprehensive single-cell multi-omic research solutions, has appointed Suresh Pisharody as its new CEO. Mr. Pisharody brings a wealth of experience in building life sciences tools and diagnostic businesses globally. His expertise in developing and implementing business strategies to enter new markets will be instrumental as the company aims to establish itself as a leader in the rapidly expanding genomics and precision medicine industries.

BioSkryb Genomics, a pioneer in developing scientifically advanced single-cell analysis molecular tools, today announced a multi-year agreement with Cooper Genomics, a leader in the reproductive health market, to license BioSkryb’s proprietary genomic amplification technology. Cooper Genomics will utilize the BioSkryb technology to enhance their preimplantation genetic testing (PGT) capabilities. The agreement will also permit Cooper Genomics to market and distribute the BioSkryb technology for the PGT and women’s reproductive health market globally.

BioSkryb Genomics, a pioneer in developing scientifically advanced single-cell analysis molecular chemistry and technology, today announced a partnership with BioXpedia A/S, a contract research laboratory providing high-quality, cost-effective services to preclinical and clinical researchers. This partnership forms a single source, end to end solution for the evaluation of multiomics in single cells supporting unprecedented target identification and therapeutic advancement.

BioSkryb Genomics, a biotech company developing advanced single-cell analysis tools, today announced the launch of the Early Access Program (EAP) for ResolveOME, a unified, single-cell workflow that amplifies the complete genome and full-length mRNA transcripts of the entire transcriptome from the same cell. This unification eliminated the need to split source material or interpret across datasets. Companies and researchers will have the opportunity to apply for the EAP at the upcoming Advances in Genome Biology and Technology (AGBT) 2022 General Meeting taking place June 6-9 in Orlando. The EAP will provide first access to BioSkryb’s ResolveOME technology and BaseJumper, a bioinformatics platform to sort, analyze, and interpret very large single-cell analysis data sets.

BioSkryb Genomics, a leader of single-cell genome amplification, and ALS Automated Lab Solutions GmbH, developers of a multi-patented spatial single cell and colony picking technology platform, today announced a U.S. distribution agreement to power comprehensive single cell plus spatial genomic analysis. The agreement was signed in December 2021. In addition, the partnership will develop single-cell genome analysis from intact tissue samples. The distribution agreement combines BioSkryb’s proprietary ResolveDNA™ technology with ALS CellCelector™ platform to drive single-cell genomic applications where the genome context matters.